ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO306

Vascular Calcification in Kidney Stone Formers: The Impact of Age and Stone Composition

Session Information

Category: Bone and Mineral Metabolism

  • 502 Bone and Mineral Metabolism: Clinical


  • Bnaya, Alon, Shaare Zedek Medical Center, Jerusalem, Jerusalem, Israel
  • Barhoum, Yehezkel, Shaare Zedek Medical Center, Jerusalem, Jerusalem, Israel
  • Kafka, Ilan Zeev, Shaare Zedek Medical Center, Jerusalem, Jerusalem, Israel
  • Shavit, Linda, Shaare Zedek Medical Center, Jerusalem, Jerusalem, Israel

Nephrolithiasis is a common condition, associated with increased cardiovascular morbidity. Previous observational studies have showed that kidney stone formers (KSF) have increased vascular calcifications (VC) and osteoporosis. However, data regarding the effect of age and stone component on VC in these patients is limited.


This is a retrospective, single center, matched case-control study. KSF with a pure stone analysis (uric acid stone or calcium oxalate) who were treated in the urology clinic of Shaare Zedek Medical Center from 2015 to 2021 were identified. Fully matched controls without history of nephrolithiasis were drawn from patients hospitalized or admitted to the emergency room of the same hospital. Abdominal aortic calcification (AAC) and vertebral bone mineral density (BMD) were assessed using available computed tomography (CT) imaging. KSF and non-KSF were compared for prevalence and severity of AAC and BMD.


A total of 335 patients were investigated, 134 with calcium oxalate stone, 67 with uric acid stone, and 134 fully matched controls. Overall, the severity of VC, measured by the AAC score, did not differ significantly between the groups. However, in patients aged <60 years, both prevalence and severity of aortic calcification were significantly higher in calcium oxalate and uric acid stone groups compared to control (55.1%, 37.8% and 21.8%, p = 0.001, for the prevalence of aortic calcification and 95.4±187.5, 85.8±166.6 and 16.3±86.6, p = 0.001, for ACC score, respectively). The prevalence of osteoporosis was similar between the groups.


In this study, the prevalence and severity of VC was higher in younger KSF. These findings may suggest premature vascular calcification among patients with nephrolithiasis, both in calcium oxalate and uric acid stone formers.